title: Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature.
abstract: Parkinson's disease (PD) affects nearly 1 million Americans with a mean onset age of 60 years. Its progressive, neurodegenerative nature, causing motor complications and affecting mood, has a considerable impact on a patient's health-related quality of life. Pharmacologic therapies are the most widely utilized treatment. The broad range of drugs for treating PD warrants an assessment of each medication's health-related outcomes, which includes consideration of clinical, economic and patient-centered outcomes. This review seeks to explore the outcomes associated with drugs frequently appearing in the literature of the past 5 years and to comment on the direction of pharmacologic research and management of PD pharmacotherapy in the future.
authors.affiliation: Ohio State University College of Pharmacy, 500 W. 12th Avenue, Columbus, OH 43210, USA.
authors.forename: Ala I
authors.initials: AI
authors.lastname: Iaconi
authors.forename: Marliese A
authors.initials: MA
authors.lastname: Zimmerman
authors.forename: Amit S
authors.initials: AS
authors.lastname: Kulkarni
authors.forename: Rajesh
authors.initials: R
authors.lastname: Balkrishnan
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents